Services for the production and stability testing of clinical grade lentiviral vector, in support of the HHS, NIH, national cancer institute (NCI), center for cancer research (CCR), pediatric oncology…
Active Purchase Order Awarded Last action
- Contract number
- 75N91025P00088
- Awardee
-
Vector Biomed Inc. UEI XJUXGT62VKL5
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $803,500
Award facts
- Opportunity
-
- Acquisition of Services for the Production and Stability Testing of Clinical Grade Lentiviral Vector Pre-Solicitation · 75N91025Q00001 · Posted Sep 24, 2024
- Contract value 100% obligated
- $803,500.00 Current and potential, with all options
- Completion date 48% complete
- Current and potential, with all options
- NAICS code
- 325414 Biological Product (except Diagnostic) Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Not Competed under SAP · 1 offer Simplified Acquisition
- Pricing
- Firm Fixed Price
- Place of performance
- Gaithersburg, MD 20878, USA
- Legislative mandates
-
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Original award | $803,500 |
About this award
The National Cancer Institute awarded a purchase order to Vector Biomed Inc. for $803,500 on November 27, 2024, for production and stability testing of clinical grade lentiviral vector in support of the Pediatric Oncology Branch.
Work is performed in Gaithersburg, Maryland. The order requires production of a minimum of 50 milligrams of GMP/clinical grade transfer plasmid and a minimum of 400 milliliters of concentrated, GMP grade lentiviral vector, along with stability testing and documentation for an Investigational New Drug application. Performance extends through November 26, 2028. The procurement was issued on a sole source basis under FAR Part 12, citing Vector Biomed's unique capability to utilize the proprietary transfer plasmid backbone required and the company's prior performance as the incumbent supplier of research and preclinical grade vector to the same program.
Description
Services for the production and stability testing of clinical grade lentiviral vector, in support of the HHS, NIH, national cancer institute (NCI), center for cancer research (CCR), pediatric oncology branch (POB)
Quick answers
Who was awarded contract 75N91025P00088?
75N91025P00088 was awarded to Vector Biomed Inc. by National Cancer Institute (National Institutes of Health) on November 27, 2024.
How much is contract 75N91025P00088 worth?
The government has obligated $803,500 on 75N91025P00088.
Was contract 75N91025P00088 competed?
The extent of competition for 75N91025P00088 was not competed under sap. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award